Effekter af Akkermansia Muciniphila og Berberin-tilskud på Insulinsensitivitet hos Nattearbejdere (Shift2Health)
Effekter af Akkermansia Muciniphila og Berberintilskud på Insulinsensitivitet hos Nattearbejdere: et Dobbeltblindt, Randomiseret, Placebokontrolleret, Crossover-studie i Shift2Health-projektet
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.
Together, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.
Based on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.
Assessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.
The primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.
These measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Miriam Ressler, PhD
- Telefonnummer: +4331654536677
- E-mail: miriam.ressler@fh-joanneum.at
Studiesteder
-
-
Styria
-
Graz, Styria, Østrig, 8020
- Rekruttering
- FH JOANNEUM University of Applied Sciences
-
Kontakt:
- Miriam Ressler, PhD
- Telefonnummer: +4331654536677
- E-mail: miriam.ressler@fh-joanneum.at
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Health care or industrial shift worker
- Employed or self-employed working ≥ 24 h/week
- Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights/month
- Night shift work duration > 3 years
- 4 or more night shifts/month
Exclusion Criteria:
- BMI of 40 kg/m² or higher
- Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women
- Bariatric surgery
- Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study
- Diagnosed diabetes type 1 or type 2
- Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH/T4 levels without stable medication for more than 3 months)
- Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)
- Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable
- Regular intake of anticoagulants
- Known allergy to any inactive or active ingredients in the study products
- Participation in other clinical intervention trials during the study
- Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: AB Group
Participants will first receive Verum (A) for 3 months. After a 4-week washout period, they will receive Placebo (B) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
|
Eksperimentel: BA Group
Participants will first receive Placbo (B) for 3 months. After a 4-week washout period, they will receive Verum (A) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change of 3-months supplementation with A. muciniphila and berberine on insulin resistance using HOMA-IR compared to placebo
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Homeostasis Model Assessment of Insulin Resistance, calculated as (fasting insulin (μU/ml) x fasting glucose (mmol/l)) / 22.5, will be assessed to calculate the change between baseline and endpoint in the two periods |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in gut microbiom composition between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Gene sequencing of the 16S rRNA is performed on the stool samples to compare microbiota diversity and relative abundance |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in FABPi between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of FABP intestinal (FABPi) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in zonulin between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of zonulin in blood (ng/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in LPB between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of lipopolysaccharide-binding protein (LPB) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in CRP between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Analysis of high-sensitive C-reactive protein (hs-CRP, mg/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in stool short-chain fatty acids (SCFA) between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
SCFA will be extracted and quantitatively analysed by GC-MS (µmol/g) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood lipid profile and cardiovascular markers between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein (HDL-C, mmol/L), and triglyceride levels (TG, mmol/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood pressure between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Systolic BP (mmHG) and diastolic BP (mmHG) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in melatonin between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
6-sulfatoxymelatonin in urine (µg/L) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in BMI between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Body mass index (BMI) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in body composition between the baseline and endpoint change in the two periods
Tidsramme: At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Bioelectrical Impedance Analysis (BIA) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in metabolomics at the end of the two periods
Tidsramme: At the beginning and the end of each intervention period (week 12, week 28)
|
Metabolomic profiles obtained with LC-MS/MS |
At the beginning and the end of each intervention period (week 12, week 28)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Sygdomme i nervesystemet
- Ernæringsforstyrrelser
- Metaboliske sygdomme
- Overernæring
- Kropsvægt
- Glukosemetabolismeforstyrrelser
- Diabetes mellitus
- Hyperinsulinisme
- Hyperglykæmi
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Tegn og symptomer
- Overvægtig
- Fedme
- Insulin resistens
- Prædiabetisk tilstand
- Glucoseintolerance
- Kronobiologiske lidelser
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 1306/2025
- 101080788 (Andet bevillings-/finansieringsnummer: Horizon Europe)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .